Financial HealthDynavax has a strong cash position with $764.0M in cash, cash equivalents, and marketable securities.
Market PositionHeplisav-B is the only two-dose adult Hepatitis B vaccine available, providing a unique market position for Dynavax.
Product GrowthHeplisav-B sales increased by 27% year over year, showcasing strong growth in the company's marketed Hepatitis B vaccine.